Your browser doesn't support javascript.
loading
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Mauro, Michael J; Hughes, Timothy P; Kim, Dong-Wook; Rea, Delphine; Cortes, Jorge E; Hochhaus, Andreas; Sasaki, Koji; Breccia, Massimo; Talpaz, Moshe; Ottmann, Oliver; Minami, Hironobu; Goh, Yeow Tee; DeAngelo, Daniel J; Heinrich, Michael C; Gómez-García de Soria, Valle; le Coutre, Philipp; Mahon, Francois-Xavier; Janssen, Jeroen J W M; Deininger, Michael; Shanmuganathan, Naranie; Geyer, Mark B; Cacciatore, Silvia; Polydoros, Fotis; Agrawal, Nithya; Hoch, Matthias; Lang, Fabian.
Afiliación
  • Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. maurom@mskcc.org.
  • Hughes TP; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia.
  • Kim DW; Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea.
  • Rea D; Adult Hematology and INSERM CIC1427, Hôpital Saint-Louis, Paris, France.
  • Cortes JE; Georgia Cancer Center, Augusta, GA, USA.
  • Hochhaus A; Universitätsklinikum Jena, Jena, Germany.
  • Sasaki K; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Breccia M; Department of Translational and Precision Medicine-Az., Policlinico Umberto I-Sapienza University, Rome, Italy.
  • Talpaz M; Division of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
  • Ottmann O; Cardiff University, Cardiff, UK.
  • Minami H; Kobe University Hospital, Kobe, Japan.
  • Goh YT; Department of Haematology, Singapore General Hospital, Bukit Merah, Singapore.
  • DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Heinrich MC; Department of Medicine, Division of Hematology and Oncology, Portland VA Health Care System and Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
  • Gómez-García de Soria V; Hospital de la Princesa, Madrid, Spain.
  • le Coutre P; Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Mahon FX; Department of Hematology, Institut Bergonié, Bordeaux, France.
  • Janssen JJWM; VU University Medical Center, Amsterdam, The Netherlands.
  • Deininger M; Versiti Blood Research Institute, Milwaukee, WI, USA.
  • Shanmuganathan N; Royal Adelaide Hospital, Adelaide, SA, Australia.
  • Geyer MB; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cacciatore S; Novartis Pharma AG, Basel, Switzerland.
  • Polydoros F; Novartis Pharma AG, Basel, Switzerland.
  • Agrawal N; Novartis Pharma AG, Basel, Switzerland.
  • Hoch M; Novartis Pharma AG, Basel, Switzerland.
  • Lang F; Department for Hematology/Oncology, Goethe University Hospital, Frankfurt am Main, Germany.
Leukemia ; 37(5): 1048-1059, 2023 05.
Article en En | MEDLINE | ID: mdl-36949155
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Neutropenia / Antineoplásicos Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Neutropenia / Antineoplásicos Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos